These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Nonsurgical treatment options for basal cell carcinoma - focus on advanced disease. Goldenberg G; Hamid O J Drugs Dermatol; 2013 Dec; 12(12):1369-78. PubMed ID: 24301238 [TBL] [Abstract][Full Text] [Related]
43. Vismodegib: A Review in Advanced Basal Cell Carcinoma. Frampton JE; Basset-Séguin N Drugs; 2018 Jul; 78(11):1145-1156. PubMed ID: 30030732 [TBL] [Abstract][Full Text] [Related]
44. Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study. Sekulic A; Migden MR; Basset-Seguin N; Garbe C; Gesierich A; Lao CD; Miller C; Mortier L; Murrell DF; Hamid O; Quevedo JF; Hou J; McKenna E; Dimier N; Williams S; Schadendorf D; Hauschild A; BMC Cancer; 2017 May; 17(1):332. PubMed ID: 28511673 [TBL] [Abstract][Full Text] [Related]
45. Oral Hedgehog Pathway Inhibition as a Means for Ocular Salvage in Locally Advanced Intraorbital Basal Cell Carcinoma. Mathis J; Doerr T; Lin E; Ibrahim SF Dermatol Surg; 2019 Jan; 45(1):17-25. PubMed ID: 30586344 [TBL] [Abstract][Full Text] [Related]
46. A retrospective comparative study of outcome with surgical excision and repair versus nonsurgical and ablative treatments for basal cell carcinoma. Mahajan S; Kalaivani M; Sethuraman G; Khaitan BK; Verma KK; Gupta S Indian J Dermatol Venereol Leprol; 2021; 87(3):348-356. PubMed ID: 33666033 [TBL] [Abstract][Full Text] [Related]
47. Vismodegib: a guide to its use in locally advanced or metastatic basal cell carcinoma. Lyseng-Williamson KA; Keating GM Am J Clin Dermatol; 2013 Feb; 14(1):61-4. PubMed ID: 23329081 [TBL] [Abstract][Full Text] [Related]
49. Vismodegib as a neoadjuvant treatment to Mohs surgery for aggressive basal cell carcinoma. Alcalay J; Tauber G; Fenig E; Hodak E J Drugs Dermatol; 2015 Mar; 14(3):219-23. PubMed ID: 25738842 [TBL] [Abstract][Full Text] [Related]
50. Safety and efficacy of vismodegib in patients with basal cell carcinoma nevus syndrome: pooled analysis of two trials. Chang AL; Arron ST; Migden MR; Solomon JA; Yoo S; Day BM; McKenna EF; Sekulic A Orphanet J Rare Dis; 2016 Sep; 11(1):120. PubMed ID: 27581207 [TBL] [Abstract][Full Text] [Related]
51. Risk of cutaneous squamous cell carcinoma after treatment of basal cell carcinoma with vismodegib. Bhutani T; Abrouk M; Sima CS; Sadetsky N; Hou J; Caro I; Chren MM; Arron ST J Am Acad Dermatol; 2017 Oct; 77(4):713-718. PubMed ID: 28780365 [TBL] [Abstract][Full Text] [Related]